U.S. drugmaker Eli Lilly pauses antibody trial over safety concerns


  • World
  • Wednesday, 14 Oct 2020

WASHINGTON, Oct. 13 (Xinhua) -- U.S. drugmaker Eli Lilly said Tuesday it has paused its trial of a combination antibody treatment for COVID-19 for safety reasons.

The company said the trial's Data Safety Monitoring Board (DSMB), an independent group of medical experts who monitor clinical trials, recommended the pause.

"The trial, evaluating Lilly's investigational neutralizing antibody as a treatment for COVID-19 in hospitalized patients, is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH)," a Lilly spokesperson said in a statement.

"Lilly is supportive of the decision by the independent DSMB to cautiously ensure the safety of the patients participating in this study," said the statement.

Neither Eli Lilly nor the NIAID, which is sponsoring the trial, have described the safety issue that prompted the decision to pause the study.

Article type: metered
User Type: anonymous web
User Status:
Campaign ID: 1
Cxense type: free
User access status: 3
   

Did you find this article insightful?

Yes
No

Next In World

UN envoy calls for action against Myanmar junta over bloodshed
Brazil's Bolsonaro says pandemic aid payments could vary in value
Irish foreign minister to meet Iran's Rouhani on nuclear deal
Mars rover Perseverance takes first spin on surface of red planet
U.S. detained nearly 100,000 migrants at U.S.-Mexico border in February: sources
Brazil variant can reinfect virus survivors; COVID-19 vaccine antibodies pass into breast milk
Saudi-led coalition says it downed six Houthi drones fired at Khamis Mushait
Belgium sets out plan for easing, with bars to reopen on May 1
In Brazil's Amazon, isolated indigenous people welcome COVID vaccine
At least 20 killed by suicide car bomb near restaurant in Somalia capital

Stories You'll Enjoy


Vouchers